Sarepta Therapeutics to Announce Third Quarter 2026 Financial ResultsBusiness Wire · 2 days ago
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)Defense World · 5 days ago
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingBusiness Wire · Oct 14, 2026
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'Benzinga · Oct 6, 2026
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPTBusiness Wire · Oct 5, 2026
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC WainwrightDefense World · Oct 5, 2026Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.22 | -$0.05 | Miss |
| May 6, 2026 | $0.98 | $3.16 | Beat |
| Feb 25, 2026 | -$1.03 | -$3.58 | Miss |
| Nov 3, 2025 | -$0.73 | -$1.80 | Miss |
| Aug 6, 2025 | $0.83 | $2.02 | Beat |
| May 6, 2025 | -$0.87 | -$4.60 | Miss |